Quietly launched three years ago, Blackthorn Therapeutics Inc. declared its intention to tackle neurobehavioral disorders in a big way, closing a $40 million series A led by founding investor Arch Venture Partners with support from Johnson & Johnson Innovation (JLABS)-JJDC Inc., Altitude Life Science Ventures, Mercury Fund, Alexandria Real Estate Equities and an undisclosed crossover fund.